Merrimack Pharmaceuticals Inc  

(Public, NASDAQ:MACK)   Watch this stock  
Find more results for MACK
+0.03 (0.55%)
Feb 12 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.17 - 5.64
52 week 5.10 - 13.84
Open 5.61
Vol / Avg. 1.66M/1.62M
Mkt cap 649.76M
P/E     -
Div/yield     -
EPS -1.00
Shares 115.57M
Beta 1.52
Inst. own 69%
May 11, 2016
Merrimack Pharmaceuticals Inc Annual Shareholders Meeting (Estimated) - 3:00PM EDT - Add to calendar
Feb 22, 2016
Q4 2015 Merrimack Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Jan 12, 2016
Merrimack Pharmaceuticals Inc at JPMorgan Healthcare Conference - Webcast
Dec 15, 2015
Merrimack Pharmaceuticals Inc at Guggenheim Boston Healthcare Conference
Dec 8, 2015
Merrimack Pharmaceuticals Inc at Oppenheimer Healthcare Conference
Nov 18, 2015
Merrimack Pharmaceuticals Inc at Jefferies Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -257.82% -81.32%
Operating margin -232.84% -64.48%
EBITD margin - -61.34%
Return on average assets -163.69% -47.60%
Return on average equity - -
Employees 306 -
CDP Score - -


1 Kendall Sq Ste B7201
CAMBRIDGE, MA 02139-1670
United States - Map
+1-617-4411000 (Phone)
+1-617-4911386 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company discovering, developing and preparing to commercialize medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has six targeted therapeutic oncology candidates in clinical development (MM-398, MM-302, MM-121, MM-111, MM-151 and MM-141). The Company’s most advanced program is its investigational agent MM-398. The Company also has multiple product candidates in preclinical development and a discovery effort advancing additional candidate medicines. The Company has an agreement to utilize its manufacturing know-how to develop, manufacture and exclusively supply bulk drug to a third party, who processes the drug into a finished product and commercializes it globally. The Company is also developing in vitro and in vivo companion diagnostics for use with each of its oncology therapeutic product candidates.

Officers and directors

Gary L. Crocker Independent Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Robert J. Mulroy President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Yasir B Al-Wakeel Chief Financial Officer and Head - Corporate Development
Age: 34
Bio & Compensation  - Reuters
William M. McClements Senior Vice President - Corporate Operations
Age: 51
Bio & Compensation  - Reuters
Edward J. Stewart Senior Vice President and President, Merrimack Healthcare Solutions, Head of Commercial
Age: 44
Bio & Compensation  - Reuters
William A. Sullivan Principal Accounting Officer
Age: 43
Bio & Compensation  - Reuters
Peter N. Laivins Head of Development
Age: 56
Bio & Compensation  - Reuters
Birgit M. Schoeberl Ph.D. Head of Discovery
Age: 42
Bio & Compensation  - Reuters
John M. Dineen Director
Bio & Compensation  - Reuters
Ulrik B. Nielsen Ph.D. Director
Age: 42
Bio & Compensation  - Reuters